Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) EPS (Basic) (2016 - 2025)

Aptevo Therapeutics' EPS (Basic) history spans 11 years, with the latest figure at -$2.23 for Q3 2025.

  • For Q3 2025, EPS (Basic) rose 99.38% year-over-year to -$2.23; the TTM value through Sep 2025 reached -$372.88, up 81.01%, while the annual FY2023 figure was $164.87, 10401.29% up from the prior year.
  • EPS (Basic) for Q3 2025 was -$2.23 at Aptevo Therapeutics, up from -$8.4 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $38.99 in Q4 2023 and bottomed at -$1237.0 in Q2 2024.
  • The 5-year median for EPS (Basic) is -$1.6 (2021), against an average of -$121.1.
  • The largest annual shift saw EPS (Basic) surged 3960.27% in 2023 before it crashed 6311.97% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$1.27 in 2021, then grew by 20.47% to -$1.01 in 2022, then soared by 3960.27% to $38.99 in 2023, then crashed by 1017.86% to -$357.86 in 2024, then skyrocketed by 99.38% to -$2.23 in 2025.
  • Per Business Quant, the three most recent readings for APVO's EPS (Basic) are -$2.23 (Q3 2025), -$8.4 (Q2 2025), and -$4.39 (Q1 2025).